Coronary heart disease (CHD) is the primary cause of death worldwide and the second in Indonesia. Acute coronary syndrome (ACS) is the most common clinical manifestation of CHD. In more than 90% of cases, the underlying cause of ACS is the narrowing of blood vessels due to atherosclerosis. A major risk factor for atherosclerosis is dyslipidemia. LDL-C is known to be the most pro-atherogenic component of cholesterol. This study was conducted to provide an overview of the lipid profile and treatment of dyslipidemia in patients with ACS who were hospitalized at RSUD Dr. Soetomo period January 2019–December 2021. This study was a descriptive observational with a retrospective study. The study materials were taken from the patients electronic medical record with the total sampling method. Out of 1061 patients diagnosed with ACS, only 259 patients met the inclusion criteria. It was found that 74.1% of patients were men, with the 55-59 age group dominating (21.6%). The most common type of diagnosis was STEMI (69.1%). The most widely prescribed anti-dyslipidemia drug was atorvastatin (95.8%). Most of the patients had dyslipidemia 67.6% had non-optimal LDL-C levels (≥100 mg/dL) 46.7% had abnormal TG levels (≥150 mg/dL) 35.1% had increased TC levels (≥200 mg/dL) and 49.8% had low HDL-C levels (<40 mg/dL). The non-optimal LDL-C levels were more commonly found in men (70.8%), in the 40-44 years age group (93.3%), and in the STEMI diagnosis group (71.5%). As many as 98.1% of ACS patients had not reached the therapeutic target of LDL-C levels and 93.4% had not reached the therapeutic target of non-LDL-C levels.

lipid profile

acute coronary syndrome

dyslipidemia

Atherosclerosis

LDL-C